Download MendeleyDiscovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase.
O'Malley, D.P., Ahuja, V., Fink, B., Cao, C., Wang, C., Swanson, J., Wee, S., Gavai, A.V., Tokarski, J., Critton, D., Paiva, A.A., Johnson, B.M., Szapiel, N., Xie, D.(2019) ACS Med Chem Lett 10: 1486-1491
- PubMed: 31620238
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00354
- Primary Citation of Related Structures:
6PDJ - PubMed Abstract:
C-terminal Src kinase (CSK) functions as a negative regulator of T cell activation through inhibitory phosphorylation of LCK, so inhibitors of CSK are of interest as potential immuno-oncology agents. Screening of an internal kinase inhibitor collection identified pyridazinone lead 1 , and a series of modifications led to optimized compound 13 . Compound 13 showed potent activity in biochemical and cellular assays in vitro and demonstrated the ability to increase T cell proliferation induced by T cell receptor signaling. Compound 13 gave extended exposure in mice upon oral dosing and produced a functional response (decrease in LCK phosphorylation) in mouse spleens at 6 h post dose.
Organizational Affiliation:
Bristol-Myers Squibb Company, Research and Development, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States.
